1 / 10

Analyzing Stryker Corporation for Investment Decision-Making

Explore reasons to sell Stryker (SYK) stock, including management changes, recalls, regulatory concerns, and better healthcare opportunities. Analyze sales, EPS estimates, and market conditions to decide on divestment. Stay informed for profitable investment choices.

bonner
Télécharger la présentation

Analyzing Stryker Corporation for Investment Decision-Making

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Recommendation: Sell Stryker (SYK) Green & Gold Fund

  2. Healthcare holdings • Abbott Labs (ABT) • Stryker Corp (SYK) • Healthcare Select ETF (XLV)

  3. Rationale for Sale • Earnings revisions by analysts and management • Recent recalls / FDA limitations / potential litigation • Slower overseas adoption of products than anticipated • New CEO, no full time CFO • Better opportunities elsewhere • Healthcare indices have rallied this year, with only modest gains by SYK • Starting in 2013, the Affordable Care Act mandates a 2.9% tax on all revenue related to medical devices • Volatility associated with the election • Potential for investor backlash in lead up to 2013

  4. Investment Information ~$600 gain 1 Year Price Graph

  5. Analyst revisions Sales estimates EPS estimates Stryker CEO Kevin Lobo: “We expect market conditions to remain challenging in Europe...”

  6. Recalls / FDA limitations • Rejuvenate hip implant recall / potential litigation • Wingspan stint for ischemic stroke recommended by the FDA only patients with no other options

  7. Better opportunities in healthcare • Healthcare indices have rallied this year, with only modest gains by SYK • Starting in 2013, the Affordable Care Act mandates a 2.9% tax on all revenue related to medical devices • Volatility associated with the election • Potential for investor backlash in lead up to 2013

  8. Management shuffle • Kevin Lobo named CEO on Oct. 1 • Currently no CFO, but former CFO Dean Bergy remains an advisor • Potential difficulties transitioning to new management

  9. Stryker manufactures medical technologies. • Original thesis: Stryker is a leading medical technology manufacturer with potential for expansion • Rationale for sale • Management shuffle • Disappointing results • Recalls, FDA notices, potential litigation • Regulatory concerns make medical devices less appealing

More Related